Considering how many of them there are these days, finding the best Lego sets can feel like an impossible task. Or like finding a brick in a haystack of bricks, actually. You can choose between ...

Illumina, Inc. (NASDAQ:ILMN) offers sequencing- and array-based solutions for genetic and genomic analysis. The one-month return of Illumina, Inc. (NASDAQ:ILMN) was -32.97%, and its shares lost 34 ...

The MiSeq desktop sequencer offers low throughput flowcells and long read lengths. It is best for small whole-genome sequencing, targeted gene sequencing, metagenomics, and CRISPR validation. The ...

They are, collectively, some of the best-designed minifigures in recent LEGO history; the Cyclops and Gambit especially stand out for their costuming and creative use of accessories. The mansion's ...

At a launch event on Feb. 20, Roche detailed plans to enter Illumina's sequencing stronghold with a new platform. Roche's platform is in testing now and scheduled to launch commercially in 2026.

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

BEIJING’S surprise move to blacklist Illumina has unleashed a frenzy among the US firm’s Chinese rivals to win market share from the gene-sequencing giant. While Illumina is still assessing the ...

Released in June 2021, the Lego Art World Map contains 11,695 pieces, making it the biggest Lego set ever made. Much more a piece of home decor than a typical model or plaything, it’s over one meter ...

Illumina’s genome sequencer, which was designed and manufactured here, was instrumental in allowing scientists globally to develop vaccines when Covid-19 first emerged. “Illumina’s presence ...

Founded in 1998, Illumina is a genetic testing company. It develops DNA sequencing and array-based life sciences technologies to enable research discovery. Illumina sells a number of DNA sequencing ...

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.